Table 1.
Baseline characteristics Mean (SD) or Number (%) | EFV-based ART (n = 1683) | DTG-based ART (n = 1464) | HIV-uninfected (n = 21,917) |
---|---|---|---|
Age, mean (SD) | 28.78 (5.73) | 28.92 (5.95) | 28.26 (3.07) |
<25 years | 454 (27.0) | 395 (27.0) | 2723 (12.4) |
25 to <30 years | 483 (28.7) | 411 (28.1) | 11,456 (52.3) |
≥30 years | 746 (44.3) | 658 (45.0) | 7738 (35.3) |
First CD4 in pregnancy | |||
>200 cells/μl | 523 (31.1) | 110 (7.5) | n/a |
≤200 cells/μl | 79 (4.7) | 20 (1.4) | n/a |
missing | 1081 (64.2) | 1334 (91.1) | n/a |
Median cells/μl | 399 | 351 | n/a |
Salaried employment | 755 (44.9) | 613 (41.9) | 11,447 (52.2) |
Secondary education or higher | 1547 (91.9) | 1365 (93.2) | 21,127 (96.4) |
Parity ≥1 | 1194 (70.9) | 1014 (69.2) | 13,754 (62.8) |
Gravidity ≥2 | 1262 (75.0) | 1075 (73.4) | 14,747 (67.3) |
Married | 159 (9.5) | 116 (7.9) | 3562 (16.3) |
Smoking during pregnancy | 31 (1.8) | 32 (2.2) | 197 (0.9) |
Alcohol during pregnancy | 148 (8.8) | 177 (12.1) | 2088 (9.5) |
Tertiary site | 863 (51.3) | 782 (53.4) | 10,557 (48.2) |
Gestational age at baseline*, mean (SD) weeks | 12.88 (3.45) | 11.85 (3.82) | 12.24 (3.02) |
<12 weeks gestational age at baseline | 484 (28.8) | 625 (42.7) | 9438 (43.1) |
Baseline⁎⁎ weight in pregnancy, mean (SD) | 65.62 (15.13) kg | 65.66 (16.14) kg | 66.51 (15.68) kg |
<50kg | 133 (7.9) | 116 (7.9) | 2195 (10.0) |
50–80kg | 780 (46.4) | 519 (35.5) | 12,682 (57.9) |
≥80kg | 184 (10.9) | 138 (9.4) | 3326 (15.2) |
Missing | 586 (34.8) | 691 (47.2) | 3714 (17.0) |
Pre-pregnancy weight, mean (SD) | 62.60 (14.85) kg | 62.80 (15.36) kg | 63.01 (14.63) kg |
<50kg | 103 (6.1) | 98 (6.7) | 1418 (6.5) |
50–80kg | 463 (27.5) | 379 (25.9) | 6548 (29.9) |
≥80kg | 93 (5.5) | 90 (6.2) | 1341 (6.1) |
Missing | 1024 (60.8) | 897 (61.3) | 12,610 (57.5) |
Medical diagnosis prior to pregnancy other than HIV | 294 (17.5) | 239 (16.3) | 3189 (14.5) |
Baseline is ART initiation for HIV-positive women, first ANC visit for HIV-uninfected women.
The baseline weight is the first weight in pregnancy at or prior to ART initiation for HIV-positive women and at or prior to the first ANC visit for HIV-uninfected women.